🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 81 of 116

  1. neratinib

    PUMA BIOTECHNOLOGY, INC.

    HER2-mutant Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  2. neratinib

    PUMA BIOTECHNOLOGY, INC.

    Breast Neoplasms

    phase 2 small molecule completed

    3 trials

  3. nilotinib

    United Therapeutics Europe Ltd

    Mucosal Lentiginous Melanoma

    phase 2 small molecule completed

    1 trial

  4. nivolumab

    Bristol-Myers Squibb

    Neoplasms by Site

    phase 2 mab completed

    1 trial

  5. nivolumab, ipilimumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma (HCC)

    phase 2 small molecule completed

    1 trial

  6. oncolytic adenovirus expressing GMCSF

    CG Oncology

    Bladder Cancer

    phase 2 mab terminated

    1 trial

  7. ondansetron

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  8. online adaptive radiotherapy

    The First People's Hospital of Lianyungang

    Cervical Cancer

    phase 2 other active

    1 trial

  9. orelabrutinib combined with rituximab regimen

    The First People's Hospital of Lianyungang

    Marginal Zone Lymphoma(MZL)

    phase 2 small molecule active

    1 trial

  10. osimertinib

    AstraZeneca

    Carcinoma

    phase 2 small molecule active

    1 trial

  11. osimertinib mesylate tablets and anlotinib hydrochloride capsules

    The First People's Hospital of Lianyungang

    Non Small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  12. oxaliplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Stomach Neoplasms

    phase 2 small molecule active

    1 trial

  13. oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab

    Takeda

    Colorectal Carcinoma

    phase 2 small molecule completed

    1 trial

  14. pCAR-19B cells

    Chongqing Precision Biotech Co., Ltd

    Acute Lymphoblastic Leukemia

    phase 2 mab active

    2 trials

  15. pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine

    United Therapeutics Europe Ltd

    Anatomic Stage I Breast Cancer AJCC v8

    phase 2 mab active

    1 trial

  16. paclitaxel/carboplatin/lapatinib

    Hospital Authority, Hong Kong

    ErbB2-Positive Stage I-III Breast Cancer

    phase 2 small molecule active

    1 trial

  17. palifosfamide

    Alaunos Therapeutics

    Adult Central Nervous System Germ Cell Tumor

    phase 2 small molecule terminated

    1 trial

  18. pazopanib (GW786034)

    GlaxoSmithKline

    Neoplasms, Uterine Cervix

    phase 2 small molecule completed

    1 trial

  19. pazopanib (GW786034) 400 mg

    GlaxoSmithKline

    Neoplasms, Breast

    phase 2 small molecule completed

    1 trial

  20. pegcrisantaspase

    Jazz Pharmaceuticals Ireland Limited

    Acute Lymphoblastic Leukemia

    phase 2 small molecule terminated

    1 trial

  21. pelareorep, Tecentriq 840 mg concentrate for solution for infusion

    ONCOLYTICS BIOTECH INC

    Patients with advanced or metastatic gastrointestinal (GI) tumors.

    phase 2 small molecule active

    1 trial

  22. pembrolizumab

    The First People's Hospital of Lianyungang

    Advanced Non-squamous Non-small-cell Lung Cancer

    phase 2 small molecule active

    1 trial

  23. pembrolizumab

    Hospital Authority, Hong Kong

    Locally Recurrent Cancer

    phase 2 small molecule active

    1 trial

  24. pembrolizumab

    The University of Hong Kong

    T-Cell Lymphoma

    phase 2 small molecule active

    1 trial

  25. pemetrexed

    United Therapeutics Europe Ltd

    Lung Cancer

    phase 2 small molecule completed

    1 trial

  26. penpulimab, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin

    The First People's Hospital of Lianyungang

    Lymphoma, Large B-Cell, Diffuse

    phase 2 small molecule active

    1 trial

  27. pepinemab + pembrolizumab

    VACCINEX, INC.

    Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)

    phase 2 small molecule completed

    1 trial

  28. pharmorubicin or pirarubicin

    The First People's Hospital of Lianyungang

    Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  29. ponatinib - Phase 1

    Takeda

    Chronic Myeloid Leukemia (CML)

    phase 2 small molecule completed

    1 trial

  30. pyrotinib and trastuzumab in combinition with neoadjuvant chemotherapy

    The First People's Hospital of Lianyungang

    HER2-positive Breast Cancer

    phase 2 small molecule active

    1 trial

  31. radiation therapy

    Children's Hospital of Fudan University

    Brain Tumor

    phase 2 other completed

    1 trial

  32. raltitrexed combined with apatinib

    Chinese PLA General Hospital

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  33. recombinant human Angiostatin protein

    CASI Pharmaceuticals

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule completed

    1 trial

  34. recombinant human endostatin

    Peking University Third Hospital

    Melanoma

    phase 2 small molecule active

    1 trial

  35. remicade (anti tumor necrosis factor inhibitor)

    Hospital Authority, Hong Kong

    Takayasu's Arteritis

    phase 2 small molecule active

    1 trial

  36. rezatapopt

    PMV Pharmaceuticals

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  37. rituximab

    United Therapeutics Europe Ltd

    Lymphoma

    phase 2 mab completed

    1 trial

  38. rolistobart, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PACLITAXEL , CARBOPLATIN , MK-4830, MK-4830, PEMETREXED , boserolimab, vibostolimab

    Merck Sharp and Dohme

    non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  39. rolistobart, MK-4830, KEYTRUDA 25 mg/mL concentrate for solution for infusion, MK-4830

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  40. rolistobart, boserolimab, MK-4830, KEYTRUDA 25 mg/mL concentrate for solution for infusion, MK-4830

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  41. self-expandable 125I radioactive seeds-loaded-stent

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cholangiocellular Carcinoma

    phase 2 other completed

    1 trial

  42. silevertinib (BDTX-1535) monotherapy

    Blackmores Limited

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  43. sintilimab

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  44. sintilimab

    The First People's Hospital of Lianyungang

    Colorectal Neoplasms

    phase 2 small molecule active

    1 trial

  45. sintiliman plus LDRT

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric Cancer

    phase 2 small molecule active

    1 trial

  46. sodium chloride 9 mg/ml (0.9%) solution for injection, LIBTAYO 350 mg concentrate for solution for infusion.

    The George Institute

    Merkel Cell Carcinoma

    phase 2 small molecule active

    1 trial

  47. ssCART-19

    The First People's Hospital of Lianyungang

    Relapsed or Refractory Acute Lymphoblastic Leukemia

    phase 2 mab active

    1 trial

  48. ssCART-19 cells combined with CD19+ feeding T cells (FTCs) infusion

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia, Adult B-Cell

    phase 2 mab active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.